SecBot SecBot
PRESS-RELEASE ·Filed Nov 13, 2026

ARQT

Arcutis Biotherapeutics, Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed3d 15h ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

The PDUFA date of February 23, 2027 is the next key catalyst. Approval would expand ZORYVE's label to infants aged 3-24 months, addressing an unmet need. Monitor FDA review and any advisory committee meeting.

DirectionNeutral
Confidencemedium
Horizonmonths

ZORYVE

▲ Bullish Named in this press release
Impact
Phase
Approved (commercial stage)
Time to market
Already approved and commercialized. The next label expansion (infant atopic dermatitis) has a PDUFA decision date of February 23, 2027.
Next catalyst
PDUFA date · Feb 23, 2027 98d

What to watchThe next hard catalyst is the FDA PDUFA decision on February 23, 2027 for ZORYVE cream 0.05% in infants aged 3-24 months with atopic dermatitis. Approval would expand the addressable patient population and support the company's 2027 revenue inflection narrative; a CRL would remove that near-term growth driver but not threaten the core commercial business, which is already generating over $500M in annual revenue.

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1
Entry
$28.26
T+0 close · Nov 13, 2026 · via day close
Latest settled
−3.93%
T+1 · $27.15
Vs SPY
−2.02%
α at T+1
Next horizon
T+5
in 3d
  1. T+0 · Nov 13 $28.26entry
  2. T+1 · 17h ago −3.93%α −2.02% · $27.15
  3. T+5 · in 3d Pending
  4. T+20 · in 27d Pending
  5. T+60 · in 3mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arcutis presented caregiver-reported outcomes from the INTEGUMENT-INFANT trial of ZORYVE cream 0.05% in infants aged 3-24 months with mild to moderate atopic dermatitis at the ACAAI meeting. The data showed improvements in itch, symptoms, and quality of life with a favorable safety profile. The sNDA for this infant indication is under FDA review with a PDUFA date of February 23, 2027.

Key Facts

  • INTEGUMENT-INFANT trial enrolled 101 infants aged 3-24 months with mild to moderate atopic dermatitis.
  • No serious adverse events or severe treatment-emergent adverse events reported; at least 97.9% had no application-site irritation.
  • 46.6% of infants achieved ≥25% improvement in itch at 10 minutes after first application, increasing to 66.7% at 4 hours.
  • Mean POEM scores decreased from 14.5 at baseline to 6.5 at Week 4, shifting from moderate to mild disease severity.
  • sNDA for ZORYVE cream 0.05% in infants aged 3-24 months is under FDA review with PDUFA target action date of February 23, 2027.
  • ZORYVE cream 0.05% is already approved in the US for children aged 2-5 years with mild to moderate atopic dermatitis.

Financial Impact

Expanding the approved age range to infants could increase the addressable patient population; 60% of children develop atopic dermatitis symptoms within their first year. No revenue estimates provided.

revenue

Risk Factors

  • FDA may issue a Complete Response Letter or request additional data.
  • Competition from other topical treatments for pediatric atopic dermatitis.
  • The ATM program filed 9 days ago adds potential dilution risk.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
86% bullish (14 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3402608

Track record

34 reports on ARQT

Performance horizon

3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +21.34% at T+60 after the Aug 5, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 13, 20263d ago Press Release Neutral 4/10 Viewing Entry $28.26 Now $27.15 −3.93% settles Feb 11
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $27.39 Now $27.15 −0.86% settles Feb 8
  3. Nov 6, 202610d ago Institutional Cluster Neutral 3/10 Entry $25.55 Now $27.15 +6.26% settles Feb 4
  4. Nov 4, 202612d ago 3/A / CLUSTER / 3 Neutral 2/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  5. Nov 4, 202612d ago 144 Neutral 3/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  6. Nov 4, 202612d ago 424B5 Bearish 4/10 Entry $27.00 Now $27.15 −0.56% settles Feb 3
  7. Nov 4, 202612d ago 8-K Neutral 5/10 No price data
  8. Nov 4, 202612d ago Press Release Mixed 6/10 Entry $27.00 Now $27.15 +0.56% settles Feb 3
  9. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
  10. Nov 2, 202614d ago 144 Neutral 2/10 Entry $32.00 Now $27.15 −15.16% settles Feb 1
Showing 10 of 34

US Market Status

Market Closed · Opens in 9h 7m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 13, 2026